ABL1 and chronic myelogenous leukemia, BCR-ABL1 positive: Molecular response, the determination of BCR‐ABL transcripts over time, is a parameter used to determine whether CML is in remission or is persisting after TKIs treatment, and it has been proposed as an indicator to stop treatment.